November 4, 2019

End Duchenne Tour Recap: Memphis, TN

PPMD’s End Duchenne Tour made a stop in Memphis, TN on Saturday, October 26. We were joined by over 60 people,  including families, an amazing group of volunteers in our kids room, six members of…

Learn More

September 24, 2019

End Duchenne Tour Recap: Wilmington, Delaware

PPMD’s End Duchenne Tour made a stop in Wilmington, Delaware on September 14. We were joined by over 100 people, including 30 families, 20 healthcare professionals and researchers, 15 industry partners, and 5 members of…

Learn More

August 14, 2019

Solid Biosciences Provides Update on IGNITE DMD Clinical Trial

Today, Solid announced that the second patient has been dosed in the higher dose cohort of the IGNITE DMD Phase I/II clinical trial of SGT-001, the company’s AAV gene transfer candidate under investigation for Duchenne….

Learn More

May 14, 2019

Solid Biosciences Provides Update on IGNITE DMD Status and New Clinical Sites

Solid Biosciences shared an update on the progress of their IGNITE DMD Phase I/II clinical trial for investigational microdystrophin gene transfer, SGT-001. The update includes news about initiating dosing for their higher dose cohort of…

Learn More

February 7, 2019

Solid Biosciences Announces Intention to Dose Escalate in IGNITE DMD Clinical Trial

Solid Biosciences announced today plans to move to a higher dose of SGT-001 in IGNITE DMD, their Phase 1/2 clinical trial evaluating SGT-001 microdystrophin gene therapy as a potential treatment for Duchenne. This decision is…

Learn More

November 13, 2018

Solid Provides Update on IGNITE DMD Clinical Trial

  Solid Biosciences Inc. today shared on a updated on the IGNITE DMD clinical trial, noting the dosing of two additional patients with SGT-001 gene transfer and the company’s plan to report preliminary results from IGNITE…

Learn More

June 18, 2018

Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001

PPMD is excited to learn that Solid Biosciences Inc. announced that the FDA has lifted the clinical hold on IGNITE DMD, the Company’s Phase I/II clinical trial for its investigational microdystrophin gene transfer, SGT-001. In…

Learn More

December 19, 2017

Understanding Currently Recruiting Gene Therapy Studies

For the last many months, we have all been watching gene therapy make headlines around the world, across various diseases. As you know, earlier this year PPMD launched a Gene Therapy Initiative to help support the exploration…

Learn More